At the news
? BEARISHIMPACT 6/10 8-K filed Jul 13, 2026 at 06:30 ET
Agenus entered into a securities purchase agreement for a ~$85M PIPE financing led by Commodore Capital, issuing shares at $3.69 along with Series A ($4.02 strike) and Series B ($5.03 strike) warrants. Proceeds will fund the Phase 3 neoadjuvant trial of botensilimab/balstilimab in colon cancer and extend operating runway through key readouts. The offering is highly dilutive relative to the $140M market cap, but the cash infusion and board designation rights for Commodore provide a governance backstop.
- ~$85M PIPE priced at $3.69 per share (with warrants), plus pre-funded warrants at $3.68
- Series A warrants exercisable at $4.02; Series B warrants at $5.03
- Series A warrants expire 30 days after 60 patients dosed in Phase 3 colon cancer trial; Series B warrants expire 30 days after pathologic response data for ≥50 patients
- Lead investor Commodore Capital Master LP receives board designation rights (two directors) upon reaching 5% beneficial ownership
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access